### Guidelines for Submitting Abstracts to GCMAS 2025:

### Technical and Clinical Scientific Studies

Irun Fast1 and U. Measure2

1 Harvard University, Cambridge, MA, USA

2 Shriners Hospitals for Children, Sacramento, CA, USA

E-mail: irunFast@harvard.edu Web: www.harvard.edu/~irunFast

#### INTRODUCTION

The GCMAS 2025 Program Committee welcomes the submission of technical or clinical scientific studies. To be considered for a podium or poster presentation at the 2025 GCMAS Conference, abstracts must be formatted as shown in this template. Abstracts are limited to two pages. The content of each page must be contained within a 160mm X 225mm (6.3” x 8.8”) area. The text should be Times New Roman 12-pt font.

TWO electronic versions must be submitted as PDF files. 1) An unblinded version (current format) and 2) a [blinded version](https://nationwidechildrens.cloud-cme.com/assets/nationwidechildrens/PDF/GCMAS/GCMAS%202025%20-%20Template%20-%20Blinded%20Abstract.docx). The first page of the publication copy should list the title of the paper, the author(s), affiliation(s), and email address of the corresponding author. The name of the presenting author should be underlined. Reviews will be blinded.

Abstracts describing original, scientific research should be comprised of the following sections: Introduction, Clinical Significance, Methods, Results, Discussion, References, Acknowledgements, and Disclosure Statement. One or two figures may be used, but the author(s) must ensure that the figures are legible when they are reduced to half size.

Citations within the text should be made using numbers [1]. References should be listed, in order, in a separate References section, formatted as shown on the next page. References should include the first author only (followed by et. al. if appropriate), year, journal, volume, and page numbers. Papers accepted for publication should be cited as “in press.”

**CLINICAL SIGNIFICANCE**

In this section, provide a succinct statement of the clinical significance of the study and/or its relevance to treatment planning.

**METHODS**

Abstracts must be submitted electronically and received by **January 20, 2025**. If you encounter any problems with the submission process, or if you have questions about the scientific program, please contact the Program Chair:

Tyler Richardson **rtr12@psu.edu**

[Click here to access Abstract submission system](https://redcap.link/2025GCMASAbstract)

**RESULTS**

|  |  |
| --- | --- |
| One or two tables and/or figures may be incorporated within the document. All tables (Table 1) and figures (Fig. 1) must be referenced in the text. All titles, captions, figure legends, and axis labels should be large enough to be readable. For tables, include a brief title above the table. For figures, include a brief caption below the figure. The use of color is encouraged to enhance readability of the figures. Large graphics files may need to be compressed before exporting the PDF file. | Figure1 |

**Table 1:** Tables and graphs may span both columns if necessary (mean± SD).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Running Speeds: | **3 m/s** | **4 m/s** | **5 m/s** | **6 m/s** |
| Stride Length: | 2.1 ± 0.3 m | 2.5 ± 0.2 m | 2.9 ± 0.3 m | 3.2 ± 0.2 m |
| Stride Rate: | 0.64 ± 0.12 Hz | 0.69 ± 0.11 Hz | 0.72 ± 0.13 Hz | 0.78 ± 0.12 Hz |

#### DISCUSSION

All abstracts that are properly formatted and submitted by the deadline will be peer reviewed. Abstracts that meet the acceptance criteria will be included in the official conference proceedings and published online. Authors of accepted abstracts will be considered for the GCMAS Best Podium and Best Poster Awards. When the first author is a student, abstracts will also be considered for the Kevin Granata Student Award.

#### REFERENCES

1. Halvorsen, K. et al. (1999) Journal of Biomechanics, 32(11):1221-1227.

2. Woltring, H. (1990) Biomechanics of Human Movement, pp. 203-237.

**ACKNOWLEDGMENTS**

Acknowledgments are optional.

**DISCLOSURE STATEMENT**

Irun Fast is the inventor of a patented technology for battery-powered sneakers and AFOs, and she is the co-founder of Rocket Shoes, a company that manufactures this technology.

U. Measure has no conflicts of interest to disclose.